๐๐ฎ๐๐๐ซ๐ฌ๐ก๐๐ง’๐ฌ ๐๐๐๐ซ-๐๐๐ซ๐ฆ ๐๐ฅ๐ข๐ฆ๐๐ญ๐ ๐๐๐ซ๐ ๐๐ญ๐ฌ ๐๐๐ฅ๐ข๐๐๐ญ๐๐ ๐๐ฒ ๐ญ๐ก๐ ๐๐๐ข๐๐ง๐๐ ๐๐๐ฌ๐๐ ๐๐๐ซ๐ ๐๐ญ๐ฌ ๐ข๐ง๐ข๐ญ๐ข๐๐ญ๐ข๐ฏ๐
Sudarshan Chemical Industries Limited announced that its near-term greenhouse gas emission-reduction targets have been validated by the Science Based Targets initiative (#SBTi), the global body that independently assesses corporate climate goals against the latest climate science.
The validated targets commit Sudarshan to a 58.8% absolute reduction in Scope 1 and Scope 2 emissions by FY2035, against an FY2025 baseline, in line with a 1.5°C pathway. The company has also committed to extending climate action across its value chain, with suppliers representing 90.8% of emissions from purchased goods and services set to adopt science-based targets of their own by FY2030.
Sudarshan will pursue these targets through a combination of operational efficiency and low-carbon energy transition measures. Key levers include improving energy efficiency across manufacturing operations, increasing the share of #renewableelectricity through a range of procurement mechanisms, and shifting towards lower-carbon fuels.
This is a noteworthy milestone for the company, since its acquisition of #HeubachGroup, a German pigment maker, in March 2025. The deal expanded Sudarshan’s manufacturing footprint from two to 19 plants across the globe.
The current validation covers #Sudarshan’s legacy operations. Post-acquisition operations will be brought within the target boundary progressively, in keeping with SBTi requirements and timelines.
“SBTi validation confirms that our targets are grounded in climate science and measurable against it. The work now is delivery efficiency gains on the ground, a steadily larger share of renewable electricity, and a shift to cleaner fuels — alongside close engagement with the suppliers who account for most of our value chain emissions.” — Shivalika Raje, Chief Sustainability Officer, #SudarshanChemicalIndustriesLimited.
source : Sudarshan Chemical Industries Limited

Comments
Post a Comment